Short answer · Medically reviewed summary · Last updated: 2026-04-07
TL;DR: Idiopathic Thrombocytopenic Purpura (ITP) was first clinically described in the 18th century, though it was not fully understood as an autoimmune condition until the mid-20th century. Today, ITP is recognized as an immune-mediated disorder characterized by isolated low platelet counts, and our approach has shifted from radical surgeries to targeted immunotherapies. When was Idiopathic Thrombocytopenic Purpura first described? The medical history of Idiopathic Thrombocytopenic Purpura dates back to 1735, when the physician Paul Gottlieb Werlhof provided the first clear clinical description of the disease.
3 people with Idiopathic Thrombocytopenic Purpura have shared their first-person experience on this question at DiseaseMaps.
What is the history of Idiopathic Thrombocytopenic Purpura?
History of Idiopathic Thrombocytopenic Purpura: when and how it was discovered, and the milestones in research since, medically reviewed.
TL;DR: Idiopathic Thrombocytopenic Purpura (ITP) was first clinically described in the 18th century, though it was not fully understood as an autoimmune condition until the mid-20th century. Today, ITP is recognized as an immune-mediated disorder characterized by isolated low platelet counts, and our approach has shifted from radical surgeries to targeted immunotherapies.
When was Idiopathic Thrombocytopenic Purpura first described?
The medical history of Idiopathic Thrombocytopenic Purpura dates back to 1735, when the physician Paul Gottlieb Werlhof provided the first clear clinical description of the disease. Werlhof observed patients presenting with spontaneous bruising and bleeding from mucous membranes, leading to the condition historically being referred to as "Morbus Werlhofii." For centuries, physicians could observe the symptoms of Idiopathic Thrombocytopenic Purpura, but they lacked the diagnostic tools to explain why the body was destroying its own platelets.
How has our understanding of Idiopathic Thrombocytopenic Purpura evolved?
For most of the 19th and early 20th centuries, the mechanisms behind Idiopathic Thrombocytopenic Purpura remained a mystery. It wasn't until 1951 that researchers Harrington and Arimura conducted a landmark experiment—injecting themselves with plasma from patients with the disease—which proved that a circulating "factor" in the blood was destroying platelets. This discovery confirmed that Idiopathic Thrombocytopenic Purpura is an autoimmune disorder, marking a definitive shift away from earlier misconceptions that the disease was purely a result of bone marrow failure or nutritional deficiencies.
What were the major milestones in treatment?
The management of Idiopathic Thrombocytopenic Purpura has undergone a dramatic transformation, moving from invasive surgical interventions to sophisticated biological therapies. Key milestones include:
- 1916: The first successful splenectomy for ITP was performed by Paul Kaznelson, which remained the standard of care for decades.
- 1950s: The introduction of corticosteroids became the primary medical therapy to suppress the immune system.
- 1980s: The development of Intravenous Immunoglobulin (IVIG) provided a way to rapidly increase platelet counts in emergencies.
- 2000s-Present: The emergence of Thrombopoietin Receptor Agonists (TPO-RAs), which stimulate the bone marrow to produce more platelets, revolutionized long-term management.
How has patient advocacy changed the landscape?
Historically, patients with Idiopathic Thrombocytopenic Purpura often felt isolated due to the rarity and "invisible" nature of the condition. In recent decades, patient-led organizations have been instrumental in shifting the focus from simply increasing platelet counts to improving patient quality of life. At DiseaseMaps.org, our community of 374 members with Idiopathic Thrombocytopenic Purpura plays a vital role in this evolution, sharing real-world experiences that help researchers understand the burden of fatigue and psychological stress that often accompanies this diagnosis.
How do modern genetics and technology impact care?
While Idiopathic Thrombocytopenic Purpura is not typically considered a classic genetic disease, modern genomic sequencing is helping clinicians distinguish ITP from inherited thrombocytopenias. Advanced technology now allows for better differentiation between primary ITP and secondary forms caused by underlying conditions like lupus or viral infections. This precision medicine approach ensures that patients receive treatments tailored to their specific immune profile rather than a "one-size-fits-all" protocol.
Next steps
- Consult a hematologist who specializes in immune-mediated blood disorders.
- Review your treatment plan regularly to discuss both platelet counts and your overall quality of life.
- Join the 374-member community at DiseaseMaps.org to share your journey and learn from others living with this condition.
- Stay informed about clinical trials for emerging therapies through the NIH Clinical Trials database.
Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.
References
- NIH Genetic and Rare Diseases Information Center (GARD): ITP Overview.
- Orphanet: Rare Disease Database (ORPHA: 854).
- OMIM (Online Mendelian Inheritance in Man): Entry #188000.
- Platelet Disorder Support Association (PDSA): History and Research Archives.
Posted Jul 7, 2017 by Theresa 4010
He described the story of Dr. William Harrington, whose career research on ITP began when he was a medical student in Boston in 1945 and cared for a young woman with ITP who died from hemorrhage. Five years later, when he was receiving his hematology training at Washington University in St. Louis, he was caring for another woman with severe bleeding, whose platelet count had not increased after splenectomy
Posted Sep 27, 2017 by jillenid 2570
Posted Sep 29, 2017 by Marília 3570
